Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01728259
Other study ID # 2011-155
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 2013
Est. completion date October 31, 2018

Study information

Verified date May 2023
Source Barbara Ann Karmanos Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an effective treatment for amyloid light-chain amyloidosis or light chain deposition disease


Description:

PRIMARY OBJECTIVES: I. Establish the maximum tolerated dose (MTD) of the combination of pomalidomide, bortezomib, and dexamethasone (PVD) to take forward in a subsequent phase 2 study. SECONDARY OBJECTIVES: I. Obtain a preliminary assessment of efficacy of PVD regimen as initial treatment of amyloid light-chain (AL) or light chain deposition disease (LCDD). OUTLINE: This is a dose-escalation study of pomalidomide and bortezomib. Patients receive pomalidomide orally (PO) on days 1-21; bortezomib intravenously (IV) on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at least every 3 months.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date October 31, 2018
Est. primary completion date October 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Understand and voluntarily sign an informed consent form - Able to adhere to protocol requirements - Histologically confirmed AL or LCDD (any time prior to screening) - Up to 1 cycle of prior therapy allowed (maximum of 120 mg total dexamethasone (or equivalent amount of prednisone), 4 days of melphalan, and/or 4 doses of velcade; at least 4 wks has to have had passed since last dose of melphalan, 2 wks since last velcade or glucocorticoid dose - Measurable light chain elevation, as defined by: - A difference between the involved immunoglobulin free light chain and uninvolved light chain and uninvolved light chain (dFLC) of >= 5 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio - EXCEPTION: during the DOSE ESCALATION PORTION of the study only, a measurable M-protein (>= 0.5 g/dL) on serum protein electrophoresis (SPEP) or a measurable urinary light chain (>= 200 mg/24 hrs) by urine protein electrophoresis (UPEP) without a dFLC meeting the above criteria is acceptable; subjects without a dFLC >= 5 mg/dL treated at the MTD will not count towards the expansion cohort - Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry - Demonstrated clonal population of plasma cells in the bone marrow or positive immunohistochemical stain with anti-light chain anti-sera of amyloid fibrils - NTproBNP < 8500 pg/mL - Absolute neutrophil count >= 1000/mm^3 - Platelet count >= 75,000/mm^3 - Serum creatinine =< 2.5 mg/dL - Total bilirubin =< 1.5 mg/dL - AST(SGOT) and ALT(SGPT) =< 3 x upper limit of normal (ULN) - All study participants must be registered into the mandatory POMALYST REMS™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ program - Disease free of prior malignancies for > or = 2 years with exception of treated basal cell or squamous cell carcinoma of the skin. Carcinoma "in situ" of the cervix or breast, or low-risk localized prostate cancer does not outright exclude patients, but such cases need to be discussed with Dr. Zonder prior to enrollment. - Females of childbearing potential (FCBP) must have negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure - Able to take aspirin (ASA;81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin), unless baseline prothrombin time [PT] or partial thromboplastin time [PTT] is >= 1.5 ULN, in which case thromboprophylaxis not required Exclusion Criteria: - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form - Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide) - Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study - Use of any other experimental drug or therapy within 28 days of baseline - Known hypersensitivity reaction or history of desquamating rash related to thalidomide or lenalidomide - Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol - Patient has >= grade 3 peripheral sensory neuropathy or >= grade 2 painful sensory neuropathy within 14 days before enrollment; (NOTE: patient with peripheral neuropathy [PN] that was previously this severe but is currently improved due to ongoing therapy [e.g., gabapentin or amitriptyline] may be eligible) - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (not including 1st degree atrioventricular (AV)-block, Wenckebach type 2nd degree heart block, or left bundle branch block; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant); note: there is no lower limit of left ventricular ejection fraction below which patients are excluded from participation - Concurrent use of other anti-cancer agents or treatments - Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C - Meets criteria for symptomatic multiple myeloma, defined as: - >= 10% monoclonal plasma cells in the marrow AND ANY OF THE FOLLOWING: - Biopsy-confirmed plasmacytoma - Lytic bone lesion(s) - Hypercalcemia without other explanation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pomalidomide
Given PO
bortezomib
Given IV
dexamethasone
Given PO
Other:
Laboratory Biomarker Analysis
Correlative studies

Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario
United States Boston University School of Medicine Boston Massachusetts
United States Colorado Blood Cancer Institute Denver Colorado
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Barbara Ann Karmanos Cancer Institute

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose defined as the dose level before 2 of 6 patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 28 days
Secondary Complete hematologic response rate (hCR) Will be estimated and reported with 95% confidence intervals. Up to 28 days
Secondary Overall hematologic response rate (partial response [PR] + complete response [CR]) Up to 28 days
Secondary Organ response rates (heart, liver, kidney) Organ responses will be tabulated and reported for all patients with cardiac, renal, hepatic, and/or neurologic involvement by amyloidosis. Up to 28 days
Secondary Overall survival Will be estimated and reported with 95% confidence interval. From date of registration to date of death, assessed up to 28 days
Secondary Progression free survival Will be estimated and reported with 95% confidence interval. Up to 28 days
See also
  Status Clinical Trial Phase
Completed NCT00520767 - Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Phase 2
Completed NCT01194791 - Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Phase 2
Completed NCT02207556 - Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial Phase 2
Completed NCT01078454 - Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Phase 3
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT00006251 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Phase 1/Phase 2
Completed NCT01072773 - Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT03499808 - S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Phase 2
Completed NCT00536601 - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors N/A
Completed NCT00224393 - Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis Phase 2
Completed NCT01199562 - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Terminated NCT00030381 - Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis Phase 1
Completed NCT00014235 - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies N/A
Completed NCT00890747 - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Phase 1
Completed NCT00025415 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Phase 1
Completed NCT01849783 - Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Phase 2
Completed NCT01053494 - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer N/A